This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.94% per year. These returns cover a period from January 1, 1988 through July 6, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
biotechs: Archive
AZN Stock Gains as COPD Drug Clears Two Late-Stage Studies
by Zacks Equity Research
AstraZeneca jumps as tozorakimab hits primary goals in two phase III COPD trials, cuts exacerbations and shows promise in a disease with limited options.
REGNPositive Net Change SNYNegative Net Change AZNPositive Net Change RHHBYPositive Net Change
biotechs medical pharmaceuticals
Novartis Bolsters Immunology Pipeline With Excellergy Deal
by Zacks Equity Research
Novartis targets IgE-driven diseases with Excellergy buy, adding a phase I anti-IgE asset to boost its immunology pipeline and allergy franchise.
NVSNegative Net Change ANIPNegative Net Change ADMANegative Net Change LQDANegative Net Change
biotechnology biotechs medical pharmaceuticals
Novo Nordisk's Awiqli Gets FDA Approval for Type II Diabetes
by Zacks Equity Research
NVO secures FDA nod for Awiqli, a once-weekly basal insulin for type II diabetes, strengthening its portfolio and showing strong efficacy in studies.
NVOPositive Net Change INONegative Net Change ADMANegative Net Change
biotechs
KOD Stock Soars on Promising Phase III Data for Eye Disease Candidate
by Zacks Equity Research
Kodiak Sciences rallies 75% as phase III GLOW2 data show Zenkuda's strong efficacy, safety and risk reduction in diabetic retinopathy patients.
INONegative Net Change ADMANegative Net Change KODPositive Net Change
biotechs
WVE Posts Interim Data From Phase I Study on WVE-007, Stock Tanks
by Zacks Equity Research
Wave Life Sciences stock plunges after interim phase I data for WVE-007 showed modest fat reduction at higher dose, despite some sustained benefits.
NVOPositive Net Change LLYPositive Net Change VKTXNegative Net Change WVEPositive Net Change
biotechs
VKTX Finishes Enrollment in Second Late-Stage Study on Obesity Drug
by Zacks Equity Research
Viking Therapeutics climbs after it completes enrollment in the second phase III obesity study for VK2735 and advances its bid in a fast-growing, competitive weight-loss market.
NVOPositive Net Change LLYPositive Net Change VKTXNegative Net Change
biotechs medical pharmaceuticals
ImmunityBio vs. Moderna: Which Biotech Has More Upside Potential?
by Sundeep Ganoria
IBRX and MRNA hinge on single-drug success, but pipeline depth, growth plans and risks set them apart in the race for biotech upside.
MRKPositive Net Change MRNANegative Net Change IBRXNegative Net Change
biotechs medical medical-devices messenger-rna pharmaceuticals vaccines
Can Gilead's Recent Acquisitions Strengthen Its Long-Term Growth Outlook?
by Zacks Equity Research
Gilead doubles down on acquisitions, adding immunology and CAR-T assets to diversify beyond HIV and strengthen its oncology pipeline.
NVSNegative Net Change BMYPositive Net Change GILDNegative Net Change
biotechnology biotechs medical pharmaceuticals
Denali Wins FDA Nod for Hunter Syndrome Drug, Stock Up
by Zacks Equity Research
DNLI surges after FDA approves Avlayah, its first commercial drug and a breakthrough Hunter syndrome therapy targeting the brain.
SNYNegative Net Change BIIBPositive Net Change DNLINegative Net Change TAKPositive Net Change
biotechnology biotechs medical pharmaceuticals
SRPT Stock Surges on Promising Early Results From siRNA Programs
by Zacks Equity Research
Sarepta Therapeutics shares surge 35% as early data from two siRNA therapies show strong target knockdown, safety and muscle delivery potential.
SRPTNegative Net Change INONegative Net Change ADMANegative Net Change
biotechs